Sana Biotechnology: Scope Goes Beyond HIP-Modified Pancreatic Islet Cells For T1D

2025-10-16 17:09:40 ET

The last time I wrote an article on Sana Biotechnology, Inc. ( SANA ), it was in a Seeking Alpha article entitled "Sana: HIP-Modified Islet Cells To Possibly Change Scope Of Type 1 Diabetes Treatment." With respect to this article, I noted the company's opportunity to change how such patients with Type 1 Diabetes [T1D] are treated. I'm happy to state that the company is still making progress on this front, and this is based on the publication of 12-week results from an investigator-sponsored trial in one patient who showed that they were able to produce insulin in a dose-dependent manner while at the same time avoiding immune rejection from an allogeneic or autologous cell therapy. Beyond the scope of 12 weeks, even better, this noted effect was shown to last over an extended period of 6 months....

Read the full article on Seeking Alpha

For further details see: